Kevin K. Buckbee - Mar 1, 2023 Form 3 Insider Report for AbbVie Inc. (ABBV)

Role
SVP, Controller
Signature
Steven L. Scrogham, attorney-in-fact for Kevin K. Buckbee
Stock symbol
ABBV
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
3
Date filed
3/10/2023, 04:06 PM
Next filing
Feb 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABBV Common Stock, $0.01 par value 7.16K Mar 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABBV Option (Right to buy) Mar 1, 2023 Common Stock 13.9K $93.50 Direct F2
holding ABBV Option (Right to buy) Mar 1, 2023 Common Stock 9.32K $105.92 Direct F3
holding ABBV Option (Right to buy) Mar 1, 2023 Common Stock 7.01K $144.54 Direct F4
holding ABBV Option (Right to buy) Mar 1, 2023 Common Stock 6.08K $149.62 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 6,918 restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. These restricted stock units vest in full on February 17, 2025, and include the right to have stock withheld for tax purposes.
F2 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 4,637 shares on 2/20/2021, as to 4,637 shares on 2/20/2022, and as to 4,637 shares on 2/20/2023.
F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 3,106 shares on 2/18/2022, as to 3,105 shares on 2/18/2023, and will become exercisable as to 3,105 shares on 2/18/2024.
F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,335 shares on 2/17/2023, as to 2,335 shares on 2/17/2024 and as to 2,335 shares on 2/17/2025.
F5 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,026 shares on February 16, 2024, as to 2,025 shares on February 16, 2025, and as to 2,025 shares on February 16, 2026.